PCRX - Pacira BioSciences, Inc.
NASDAQ
->
Healthcare
->
Drug Manufacturers—Specialty & Generic
Parsippany,
United States
Type: Equity
PCRX price evolution
PCRX
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $153.3 | $99.12 | $86.81 | $35.55 |
| Short term investments | $125.28 | $136.07 | $133.96 | $138.45 |
| Net receivables | $105.56 | $96.96 | $99.08 | $93.2 |
| Inventory | $104.35 | $96.52 | $92.13 | $92.98 |
| Total current assets | $509.99 | $447.25 | $429.32 | $376.11 |
| Long term investments | $38.46 | $35.55 | $35.63 | $40.57 |
| Property, plant & equipment | $234.95 | $239.18 | $246.15 | $249.7 |
| Goodwill & intangible assets | $646.5 | $660.82 | $675.14 | $689.47 |
| Total noncurrent assets | $1064.39 | $1087.21 | $1113.06 | $1147.3 |
| Total investments | $163.74 | $171.62 | $169.58 | $179.02 |
| Total assets | $1574.39 | $1534.46 | $1542.38 | $1523.42 |
| Current liabilities | ||||
| Accounts payable | $15.7 | $16.51 | $24.21 | $17.26 |
| Deferred revenue | ||||
| Short long term debt | $17.44 | $17.27 | $28.48 | $19.8 |
| Total current liabilities | $97.38 | $93.66 | $108.91 | $98.7 |
| Long term debt | $568.6 | $573.03 | $592.23 | $605.36 |
| Total noncurrent liabilities | $606.87 | $609.25 | $625.49 | $656.68 |
| Total debt | $586.04 | $590.3 | $620.71 | $625.16 |
| Total liabilities | $704.26 | $702.91 | $734.41 | $755.38 |
| Shareholders' equity | ||||
| Retained earnings | -$106.8 | -$131.67 | -$142.52 | -$168.29 |
| Other shareholder equity | $0.25 | -$0.01 | -$0.17 | -$0.14 |
| Total shareholder equity | $870.13 | $831.55 | $807.98 | $768.04 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $153.3 | $104.14 | $585.58 | $99.96 |
| Short term investments | $125.28 | $184.51 | $70.83 | $421.7 |
| Net receivables | $105.56 | $98.4 | $96.32 | $53.05 |
| Inventory | $104.35 | $96.06 | $98.55 | $64.65 |
| Total current assets | $509.99 | $498.33 | $866.05 | $651.62 |
| Long term investments | $38.46 | $64.38 | $21.99 | $109.48 |
| Property, plant & equipment | $234.95 | $254.39 | $264.81 | $211.18 |
| Goodwill & intangible assets | $646.5 | $703.79 | $769.14 | $196.07 |
| Total noncurrent assets | $1064.39 | $1182.87 | $1209.31 | $622.89 |
| Total investments | $163.74 | $248.89 | $92.82 | $531.18 |
| Total assets | $1574.39 | $1681.2 | $2075.35 | $1274.51 |
| Current liabilities | ||||
| Accounts payable | $15.7 | $15.22 | $10.54 | $10.43 |
| Deferred revenue | $10.13 | |||
| Short long term debt | $17.44 | $42.77 | $382.59 | $157.07 |
| Total current liabilities | $97.38 | $147.77 | $521.12 | $253.33 |
| Long term debt | $568.6 | $655.82 | $746.26 | $384.06 |
| Total noncurrent liabilities | $606.87 | $758.42 | $823.83 | $401.5 |
| Total debt | $586.04 | $763.39 | $1128.85 | $541.13 |
| Total liabilities | $704.26 | $906.19 | $1344.94 | $654.83 |
| Shareholders' equity | ||||
| Retained earnings | -$106.8 | -$148.75 | -$211.9 | -$253.88 |
| Other shareholder equity | $0.25 | $0.14 | $0.17 | $0.32 |
| Total shareholder equity | $870.13 | $775.01 | $730.41 | $619.69 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $181.24 | $163.93 | $169.47 | $160.34 |
| Cost of revenue | $47.69 | $39.75 | $48.21 | $49.02 |
| Gross Profit | $133.55 | $124.18 | $121.26 | $111.32 |
| Operating activities | ||||
| Research & development | $19.46 | $20.83 | $18.82 | $17.14 |
| Selling, general & administrative | $65.8 | $67.95 | $64.85 | $70.84 |
| Total operating expenses | $100.38 | $106.45 | $81.38 | $114.41 |
| Operating income | $33.17 | $17.72 | $39.88 | -$3.09 |
| Income from continuing operations | ||||
| EBIT | $37.11 | $20.07 | $41.72 | -$16.89 |
| Income tax expense | $8.85 | $5.74 | $12.09 | -$6.94 |
| Interest expense | $3.39 | $3.46 | $3.87 | $9.59 |
| Net income | ||||
| Net income | $24.87 | $10.86 | $25.76 | -$19.54 |
| Income (for common shares) | $24.87 | $10.86 | $25.76 | -$19.54 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $674.98 | $666.82 | $541.53 | $429.65 |
| Cost of revenue | $184.67 | $199.29 | $140.25 | $117.33 |
| Gross Profit | $490.31 | $467.53 | $401.28 | $312.32 |
| Operating activities | ||||
| Research & development | $76.26 | $84.8 | $55.55 | $59.42 |
| Selling, general & administrative | $269.44 | $254.52 | $199.34 | $193.52 |
| Total operating expenses | $402.63 | $407.5 | $311.35 | $265.97 |
| Operating income | $87.67 | $60.02 | $89.92 | $46.35 |
| Income from continuing operations | ||||
| EBIT | $82.01 | $53.28 | $88.15 | $45.76 |
| Income tax expense | $19.75 | -$2.61 | $14.42 | -$125.43 |
| Interest expense | $20.31 | $39.98 | $31.75 | $25.67 |
| Net income | ||||
| Net income | $41.95 | $15.91 | $41.98 | $145.52 |
| Income (for common shares) | $41.95 | $15.91 | $41.98 | $145.52 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | $24.87 | $10.86 | $25.76 | -$19.54 |
| Operating activities | ||||
| Depreciation | $18.48 | $18.43 | $19.05 | $19.6 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $12.42 | $12.53 | $10.96 | $11.99 |
| Total cash flows from operations | $47.58 | $44.44 | $43.5 | $19.13 |
| Investing activities | ||||
| Capital expenditures | -$1.8 | -$3.39 | -$3.4 | -$6.57 |
| Investments | $10.17 | -$0.95 | $10.73 | $72.75 |
| Total cash flows from investing | $8.37 | -$4.34 | $7.33 | $66.18 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $1.14 | $0.03 | $3.25 | $0.33 |
| Net borrowings | -$2.81 | -$27.81 | -$2.81 | -$154.24 |
| Total cash flows from financing | -$1.78 | -$27.79 | $0.44 | -$153.91 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $54.18 | $12.31 | $51.27 | -$68.59 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $41.95 | $15.91 | $41.98 | $145.52 |
| Operating activities | ||||
| Depreciation | $75.57 | $91.5 | $28.55 | $19.91 |
| Business acquisitions & disposals | -$32 | -$424.04 | ||
| Stock-based compensation | $47.9 | $48.09 | $42.25 | $39.92 |
| Total cash flows from operations | $154.65 | $145.27 | $125.72 | $77.03 |
| Investing activities | ||||
| Capital expenditures | -$15.16 | -$30.08 | -$45.87 | -$37.8 |
| Investments | $92.7 | -$163.11 | $449.12 | -$239.81 |
| Total cash flows from investing | $77.54 | -$225.19 | -$20.79 | -$277.61 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $4.75 | $27.34 | $26.66 | $102.47 |
| Net borrowings | -$187.68 | -$428.87 | $359.2 | $125.43 |
| Total cash flows from financing | -$183.03 | -$401.53 | $380.69 | $222.3 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $49.16 | -$481.44 | $485.62 | $21.73 |
News
Fundamentals
| Market cap | $1.22B |
|---|---|
| Enterprise value | $1.65B |
| Shares outstanding | 46.48M |
| Revenue | $674.98M |
|---|---|
| EBITDA | $157.58M |
| EBIT | $82.01M |
| Net Income | $41.95M |
| Revenue Q/Q | 5.40% |
| Revenue Y/Y | 1.22% |
| P/E ratio | 29.08 |
|---|---|
| EV/Sales | 2.45 |
| EV/EBITDA | 10.49 |
| EV/EBIT | 20.16 |
| P/S ratio | 1.81 |
| P/B ratio | 1.40 |
| Book/Share | 18.71 |
| Cash/Share | 3.30 |
| EPS | $0.90 |
|---|---|
| ROA | 2.72% |
| ROE | 5.12% |
| Debt/Equity | 0.81 |
|---|---|
| Net debt/EBITDA | 3.50 |
| Current ratio | 5.24 |
| Quick ratio | 4.17 |